UK biotech raised £516M in venture capital in Q1 2026 alone - up 17% quarter on quarter. These 13 active London investors are writing checks for life science companies in 2026.
London is Europe's largest biotech funding hub and part of the UK's golden triangle with Oxford and Cambridge. Deal volume rose 60% in Q1 2026 compared to the same period in 2025.
The capital in 2026 is moving into AI-driven drug discovery, cell and gene therapy, oncology, and GLP-1-adjacent platforms. Pure platform plays without IND-enabling data close less often.
What gets funded: companies with clear therapeutic hypotheses, credible clinical development paths, and IP protection. Early preclinical assets without validation data rarely move past a first call.
Set up an Ellty data room with your preclinical data package, IP summary, and cap table before reaching out. London biotech VCs ask for these before second meetings.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| 4BIO Capital | Pre-A to Series B | £5M-£50M+ | Cell therapy, gene therapy, RNA, immune oncology | 4biocapital.com |
| SV Health Investors | Seed to Series C+ | $5M-$100M+ | Therapeutics, dementia, medtech, growth equity | svhealthinvestors.com |
| Abingworth | Seed to late-stage | $10M-$100M+ | Late-stage biopharma, oncology, rare disease | abingworth.com |
| LifeArc Ventures | Seed to Series B | £3M-£30M+ | Therapeutics, rare disease, autoimmune, oncology | lifearcventures.com |
| Syncona | Seed to clinical stage | £10M-£50M+ | Gene therapy, cell therapy, rare disease | synconaltd.com |
| Novo Holdings | Series A to growth | $20M-$200M+ | Biopharma, life science, medtech | novoholdings.dk |
| Sofinnova Partners | Seed to Series B | €2M-€50M+ | Biopharma, medtech, oncology, CNS | sofinnovapartners.com |
| Oxford Science Enterprises | Seed to Series B | £1M-£20M+ | University spinouts, therapeutics, medtech, deeptech | oxfordscienceenterprises.com |
| IQ Capital | Seed to Series B | £500K-£10M | Life sciences, deeptech, AI drug discovery | iqcapital.vc |
| Amadeus Capital Partners | Seed to Series B | £1M-£15M | Digital health, life sciences, AI, medtech | amadeuscapital.com |
| Parkwalk Advisors | Seed to growth | £500K-£5M+ | MedTech, life sciences, university spinouts | parkwalk.vc |
| Octopus Ventures | Seed to Series B | £1M-£10M+ | Healthtech, life sciences, MedTech | octopusventures.com |
| Future Planet Capital | Seed to Series B | £500K-£5M+ | Life sciences, biotech, blue economy, deeptech | futureplanetcapital.com |
See which biotech VCs open your pitch
Build an Ellty data room. Track which London life science investors open it.
Start free 14-day trialWhat is a London biotech investor?
A London biotech investor backs drug discovery, cell and gene therapy, medical devices, digital health, and AI-driven life science platforms. They range from specialist oncology investors to university spinout funds covering the full development spectrum.
Specialists like 4BIO Capital and SV Health read IND-enabling data packages natively. They check your therapeutic hypothesis and IP position before evaluating team structure.
Check sizes run from £500K at Parkwalk to $200M+ at Novo Holdings. Most seed biotech rounds in London land between £3M and £15M.
London's biotech output includes Autolus Therapeutics, Centessa Pharmaceuticals, and Isomorphic Labs. Compare London healthtech investors and London AI investors to understand how technical diligence differs across life science subsectors.
The biotechs raising well in 2026 have compelling science, a credible path to clinical proof-of-concept, and a team that has done this before. The bar for a first meeting is higher than it was two years ago.
13 London biotech investors
1. 4BIO Capital
4BIO Capital is a London-based specialist in advanced therapies - cell therapy, gene therapy, RNA, and immune oncology. They led Cytospire Therapeutics' oversubscribed £61M Series A in May 2026 and co-founded Trogenix, which raised £70M in October 2025.
- Recent Deals: Cytospire £61M Series A lead (May 2026); Ray Therapeutics $125M Series B (Apr 2026); Trogenix £70M Series A co-founder (Oct 2025); 25 portfolio companies; Araris Biotech acquired by Taiho for $1.1B (Mar 2025)
- LinkedIn: 4BIO Capital LinkedIn
- Sector Focus: Cell therapy, gene therapy, RNA therapeutics, immune oncology
- Stage Focus: Pre-A to Series B
- Location: London, UK
- Website: 4biocapital.com
2. SV Health Investors
SV Health Investors manages $4B in AUM and has backed 200+ companies in 30 years. The British Business Bank committed $100M as a cornerstone to their new SV8 Biotech Fund in December 2025. Mestag Therapeutics announced $40M financing in March 2026 with SV Health support.
- Recent Deals: Mestag $40M (Mar 2026); Artios $115M Series D (Nov 2025); TRexBio $50M (Jan 2026); SV8 fund with $100M BBB cornerstone (Dec 2025); 10 investments in 2025
- LinkedIn: SV Health Investors LinkedIn
- Sector Focus: Therapeutics, dementia, medtech, healthcare growth equity
- Stage Focus: Seed to Series C+
- Location: London and Boston
- Website: svhealthinvestors.com
3. Abingworth
Abingworth is a London-based biopharma investor acquired by Carlyle with offices in London, New York, and San Francisco. They backed Cytospire's $83M Series A in May 2026 and R1 Therapeutics' $77.5M Series A in March 2026. Their $356M fund targets late-stage programs.
- Recent Deals: Cytospire $83M Series A (May 2026); R1 Therapeutics $77.5M Series A (Mar 2026); 9 investments in 2025; $356M late-stage biopharma fund deployed
- LinkedIn: Abingworth LinkedIn
- Sector Focus: Late-stage biopharma, oncology, rare disease, immunology
- Stage Focus: Seed to late-stage
- Location: London, New York, San Francisco
- Website: abingworth.com
4. LifeArc Ventures
LifeArc Ventures had its most active year ever in 2025, investing in four new companies and participating in two Series B rounds. They led Tribune Therapeutics' €23M Series A in 2025 and joined Cytospire's $83M round in May 2026.
- Recent Deals: Cytospire $83M (May 2026); GlycoEra $130M Series B (2025); Exciva €51M Series B (2025); Tribune Therapeutics €23M Series A lead (2025); 20 portfolio companies at year-end 2025
- LinkedIn: LifeArc Ventures LinkedIn
- Sector Focus: Therapeutics, rare disease, autoimmune, oncology, IPF
- Stage Focus: Seed to Series B
- Location: London, UK
- Website: lifearcventures.com
5. Syncona
Syncona is a London-listed life science investment company building and funding global leaders in cell and gene therapy. Their portfolio of 14 companies includes Beacon Therapeutics (Series C, Dec 2025) and Autolus Therapeutics, which received FDA approval for its CAR-T therapy Aucatzyl.
- Recent Deals: Beacon Therapeutics $24.5M follow-on to Series C (Dec 2025); Autolus FDA approval for Aucatzyl (2025); £765M portfolio across 14 companies; Capital Markets Day (Mar 2026)
- LinkedIn: Syncona LinkedIn
- Sector Focus: Gene therapy, cell therapy, rare disease, ophthalmology
- Stage Focus: Seed to clinical stage
- Location: London, UK
- Website: synconaltd.com
Share your biotech deck with trackable links
Use Ellty to track which London life science investors open your data room.
Start free 14-day trial6. Novo Holdings
Novo Holdings is the holding company for the Novo Nordisk Foundation with $93B in total AUM and offices in London, Copenhagen, Boston, and Singapore. They co-led Coultreon Biopharma's $125M Series A in April 2026 and backed Ray Therapeutics' $125M Series B.
- Recent Deals: Coultreon Biopharma $125M Series A co-lead (Apr 2026); Ray Therapeutics $125M Series B (Apr 2026); GlycoEra $130M Series B (2025); Hemab IPO (Jun 2026); 147 investments, $7.8B deployed
- LinkedIn: Novo Holdings LinkedIn
- Sector Focus: Biopharma, life science, medtech, sustainability
- Stage Focus: Series A to growth
- Location: London, Copenhagen, Boston, Singapore
- Website: novoholdings.dk
7. Sofinnova Partners
Sofinnova Partners closed its Capital XI fund at €650M ($750M) in November 2025, greatly exceeding its target. They backed T-Therapeutics' $91M Series A extension in Cambridge and invested in AAVantgarde's $141M Series B. Their Biovelocita II accelerator fund launched in March 2026.
- Recent Deals: T-Therapeutics $91M Series A extension (2025); AAVantgarde $141M Series B (2025); Biovelocita II €165M accelerator (Mar 2026); Capital XI €650M close (Nov 2025)
- LinkedIn: Sofinnova Partners LinkedIn
- Sector Focus: Biopharma, medtech, oncology, CNS, cardio-metabolic, rare disease
- Stage Focus: Seed to Series B
- Location: London, Paris, Milan
- Website: sofinnovapartners.com
8. Oxford Science Enterprises
Oxford Science Enterprises backs University of Oxford spinouts and has raised £850M+ from global investors. They backed Beacon Therapeutics' Series C in January 2026 and Scripta Therapeutics' €10M+ round in November 2025. Their £3B+ co-investment platform spans 110 companies.
- Recent Deals: Beacon Therapeutics Series C (Jan 2026); Scripta Therapeutics €10M+ (Nov 2025); Valink Therapeutics $11.8M Pre-A (Oct 2025); 11 investments in 2025; 110 portfolio companies
- LinkedIn: Oxford Science Enterprises LinkedIn
- Sector Focus: University spinouts, therapeutics, medtech, deep tech
- Stage Focus: Seed to Series B
- Location: Oxford and London, UK
- Website: oxfordscienceenterprises.com
9. IQ Capital
IQ Capital has £1B+ in deep tech AUM and backs life sciences and AI drug discovery from London and Cambridge. They invested in Trogenix's £70M Series A in October 2025 via their portfolio and backed Nu Quantum's $60M Series A in December 2025.
- Recent Deals: Nu Quantum $60M Series A (Dec 2025); Gravis Robotics $23M (Nov 2025); Trogenix £70M Series A (Oct 2025); £400M fourth fund; £1B+ total AUM
- LinkedIn: IQ Capital LinkedIn
- Sector Focus: Life sciences, AI drug discovery, deeptech, quantum
- Stage Focus: Seed to Series B
- Location: London and Cambridge, UK
- Website: iqcapital.vc
10. Amadeus Capital Partners
Amadeus Capital Partners backs digital health and life sciences from their London HQ with a £110M Technology Fund and £80M APEX Fund. They invest at seed and Series A, with a focus on AI-driven healthcare and medical technology.
- Recent Deals: £110M Amadeus V Technology Fund; £80M Amadeus APEX Fund; 190+ portfolio companies; digital health and life science active mandate; 2025-2026 deploying
- LinkedIn: Amadeus Capital Partners LinkedIn
- Sector Focus: Digital health, life sciences, AI, medtech, biotech
- Stage Focus: Seed to Series B
- Location: London and Cambridge, UK
- Website: amadeuscapital.com
11. Parkwalk Advisors
Parkwalk Advisors invests in UK university spinouts across MedTech, life sciences, and deeptech with £450M under management. They write first checks into IP-rich companies from Oxford, Cambridge, and Imperial College.
- Recent Deals: Quantum Motion Seed (May 2026); xWatts Seed (Feb 2026); 248 total investments; 8 IPOs; £450M AUM; MedTech and life science mandate active
- LinkedIn: Parkwalk Advisors LinkedIn
- Sector Focus: MedTech, life sciences, university spinouts, deeptech
- Stage Focus: Seed to growth
- Location: London, UK
- Website: parkwalk.vc
12. Octopus Ventures
Octopus Ventures backs healthtech and life science founders from seed to Series B. They write £1M-£10M+ first checks and have an active UK health and medtech portfolio. Their 18 investments in 2025 included health and deep tech companies.
- Recent Deals: 18 investments in 2025; 6 investments in early 2026; active healthtech and medtech portfolio; UK market focus; seed to Series B mandate
- LinkedIn: Octopus Ventures LinkedIn
- Sector Focus: Healthtech, life sciences, medtech, deep tech
- Stage Focus: Seed to Series B
- Location: London, UK
- Website: octopusventures.com
13. Future Planet Capital
Future Planet Capital backs life science and blue economy spinouts from London with a global reach. They have a track record in nuclear fusion, agtech, and semiconductors, and invest in SDG-aligned companies from top universities across the UK.
- Recent Deals: Life sciences, agtech, and deeptech portfolio companies; Birmingham regional team active; UK-wide spinout mandate; SDG-aligned portfolio; 2025-2026 active
- LinkedIn: Future Planet Capital LinkedIn
- Sector Focus: Life sciences, biotech, blue economy, deeptech, agtech
- Stage Focus: Seed to Series B
- Location: London and Birmingham, UK
- Website: futureplanetcapital.com
How to find active London biotech investors
Check each fund's last investment date and whether that investment was in your specific area - oncology, rare disease, gene therapy, and CNS are all different mandates. A fund that only backs oncology may pass on rare disease regardless of the quality.
Ask which partner covers your therapeutic modality. 4BIO has partners for gene therapy, cell therapy, and immune oncology. Reaching the right expert directly accelerates the process.
Read how to prepare for due diligence and virtual data room examples. Have your data package, regulatory strategy, and CMC summary in an Ellty data room before any intro meeting.
What London biotech VCs read before your pitch
London biotech investors want your IND-enabling data plan before almost anything else. They evaluate whether the preclinical package is sufficient to de-risk the first human study.
The second filter is IP coverage. A therapeutic with freedom-to-operate, composition of matter patents, and a defensible moat attracts more capital than a strong compound with weak IP.
The third is the development team. Investors want to see at least one founder or advisor with Phase 2 or later clinical experience. Use Ellty to share your team credentials and data package with trackable links before pitching.
Where to meet London biotech investors
The BIO International Convention and UK Biotech Day are where most London biotech VCs show up in person. SV Health and 4BIO Capital attend UK Biotech Day annually.
Oxford Biotech Society's OxBio Summit 2026 featured partners from F-Prime and other London-adjacent funds. These events get you in front of the right people without cold outreach.
Compare London proptech investors and London SaaS investors to understand how life science diligence differs from software-focused rounds.
How to pitch a London biotech investor
Four steps for life science fundraising in London in 2026. Each step reflects how biotech VCs screen deals.
- 1.Lead with your IND-enabling data plan, not the scienceShow the preclinical path to first-in-human studies. Investors gate on clinical readiness before team slides.
- 2.Show your IP coverage and freedom to operateHave a clear IP landscape analysis ready. Composition of matter patents accelerate biotech due diligence.
- 3.Name your clinical development team upfrontInvestors want Phase 2 experience in the room. Name advisors and KOLs before the first meeting.
- 4.Put everything in one trackable data roomUpload preclinical data and CMC summary to Ellty. Know who reviews your technical package.
How Ellty helps you land a London biotech investor
You have the list. Now prepare your materials. Biotech VCs ask for data packages and IP docs fast.
- 1.Upload your preclinical data and regulatory planPut technical docs in one secure room. Investors check these before the team deck.
- 2.Lock access to your IP and CMC documentsRequire email before investors view sensitive files. Use screenshot protection on trade secrets.
- 3.Track which investors open your data packageSee if VCs dig into your preclinical data or jump to financials. Follow up with those who reviewed.
Common questions from London biotech founders
- Most want at least target validation and a credible IND-enabling plan. A hypothesis with no data is a hard pass.
- Not required at pre-seed, but by Series A most investors want clinical development experience in the team.
- Specialists like 4BIO and SV Health if you are advanced therapy. Generalists work for early digital health.
- Before first outreach. Put your data package and IP summary in an Ellty room before emailing anyone.
- No IP coverage and no clinical development path. Investors pass fast on strong science with weak moats.
- Target five to eight funds with the right modality mandate. Track who opens your room and follow up first.
